Friedrich Stölzel

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Robert Zeiser, Andreas Burchert, Claudia Lengerke et al. · Leukemia · 2015 · 535 citations · Full text

Transplantation, Stem Cell Transplantation, Transplantation Medicine +9

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10

Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium

Malte von Bonin, Friedrich Stölzel, Anja Goedecke et al. · Bone Marrow Transplantation · 2008 · 302 citations

Platelet Lysate-containing Medium, Thrombosis, Third-party Msc +7

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Nimitha R. Mathew, Francis Baumgartner, Lukas M. Braun et al. · Nature Medicine · 2018 · 283 citations · Full text

Cell Therapy, Flt3-itd-mutant Leukemia Cells, Immunology +7

Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System

Christoph Röllig, Martin Bornhäuser, Christian Thiede et al. · Journal of Clinical Oncology · 2011 · 262 citations · Full text